Compare Inovio Pharmaceuticals Inc (INO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Riot Platforms Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M), while Riot Platforms Inc trades at $20.35 (market cap $7.59B). The key difference: Riot Platforms Inc is far larger — about 96.6× Inovio Pharmaceuticals Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | RIOT | |
|---|---|---|
Market Cap | $78.55M | $7.59B |
Sector | Health | Technology |
52-Week High | $2.87 | $28.67 |
52-Week Low | $0.66 | $11.33 |
Enterprise Value | $49.56M | $8.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
RIOT Platforms trades at $20.32, up 4.74% today, amid strong technical resistance near $21-$23 levels. The stock shows bearish momentum despite recent positive news about a $9.1 billion AI infrastructure deal with Anthropic. Fundamentally, the company continues to post significant losses with a -196.28% net income margin, though revenue growth remains steady at $675 million projected for 2026.
While analyst consensus remains overwhelmingly bullish with a $33.40 price target, investors face substantial execution risks as RIOT transitions from bitcoin mining to AI infrastructure. The company's persistent negative cash flow and high valuation multiples present challenges despite the transformative potential of the Anthropic partnership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
